Vaccination campaign picks up speed around the world
The campaign to vanquish the coronavirus is picking up speed in places, with Britain beginning to dispense the second vaccine in its arsenal Monday. But authorities in France and elsewhere in europe are coming under fire for slow roll-outs and delays.
In the US, Government officials reported that vaccinations have accelerated markedly after a sluggish start. Dr Anthony Fauci, the nation’s top infectious disease expert, said over the weekend that 1.5 million shots were administered in 72 hours, bringing the total over the past three weeks to about four million.
Britain on Monday became the first nation to start using the COVID-19 vaccine developed by Astrazeneca and Oxford University, ramping up its nationwide inoculation campaign amid soaring infection rates blamed on a new and seemingly more contagious variant of the virus.
Brian Pinker, an 82-year-old dialysis patient, received the first shot at Oxford University Hospital, saying in a statement: “I can now really look forward to celebrating my 48th wedding anniversary.”
Britain’s vaccination programme began December 8 with the shot developed by Pfizer and its German partner Biontech.
The country has recorded more than 50,000 new coronavirus infections a day over the past six days, and deaths have climbed past 75,000, one of the worst tolls in Europe.
Prime Minister Boris Johnson announced a wave of near-lockdowns the weekend before Christmas and warned on Monday that “tough, tough” weeks lie ahead and that tighter restrictions are coming soon: “If you look at the numbers, there’s no question we will have to take tougher measures.”
Israel appears to be among the world leaders in the vaccination campaign, inoculating over one million people, or roughly 12 per cent of its population, in just over two weeks. The effort has been boosted by a high-quality, centralised health system, and the country’s small size and concentrated population.
Elsewhere, France’s cautious approach appears to have backfired, leaving just a few hundred people vaccinated after the first week and rekindling anger over the Government’s handling of the pandemic.
The slow roll-out has been blamed on mismanagement, staffing shortages over the holidays, and a complex consent policy designed to accommodate vaccine scepticism among the French.
“It’s a State scandal,” Jean Rottner, president of the Grand Est region of eastern France, said on France-2 television. “Getting vaccinated is becoming more complicated than buying a car.”
Health Minister Olivier Veran promised that by the end of Monday “several thousand” people will have been vaccinated, with the tempo picking up through the week. But that would still leave France well behind its neighbours.
French media broadcast charts comparing vaccine figures in various countries: In France, a nation of 67 million people, just 516 people were vaccinated in the first six days, according to the French health ministry. Germany’s firstweek total surpassed 200,000 while Italy’s was over 100,000. Millions have been vaccinated in the US and China.
The European Union likewise faced growing criticism about the slow roll-out of COVID-19 shots across the 27-nation bloc of 450 million inhabitants.
EU Commission spokesman Eric Mamer said the main problem “is an issue of production capacity, an issue that everybody is facing”.
The EU has sealed six vaccine contracts with a variety of manufacturers, but only the Pfizer-biontech vaccine has been approved for use so far across the EU. The EU’S drug regulators are expected to decide on Wednesday whether to recommend authorising the Moderna vaccine.
Aspects of Britain’s vaccination plans have also spurred controversy.
British health authorities want to give the first dose to as many people as possible right away, rather than holding the vaccine in reserve to ensure recipients get their second shot on time a few weeks later. The plan requires stretching out the time between doses to as much as 12 weeks.
While two doses are required to fully protect against COVID19, one dose offers a high level of protection.
Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said policymakers are being forced to balance the potential risks and benefits in the middle of the disaster.